High-risk prostate cancer. Review.;Cancer de la prostate à haut risque de progression. Article de revue du comité de cancérologie de l'association française d'urologie

Progres en Urologie

Volumn 21, Issue 13, 2011, Pages 901-908

  Rozet, F ^a,l   Hennequin, C ^b,l   Fromont, G ^c,l   Mongiat Artus, P ^b,l   Bastide, C ^d,l   Beuzeboc, P ^e,l   Cormier, L ^f,l   Eiss, D ^g,l   Peyromaure, M ^h,l   Richaud, P ^i,l   Salomon, L ^j,l   Soulie M ^k,l  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NORD   (France)

^e INSTITUT CURIE   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Hôpital Cochin ^*  (France)

ⁱ INSTITUT BERGONIÉ   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k CHU RANGUEIL   (France)

^l Comité de cancérologie de l'AFU ^*  (France)

more..

Author keywords

Androgen deprivation therapy; Combined treatments; High risk prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

GONADORELIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD; CANCER INVASION; CANCER STAGING; EVIDENCE BASED MEDICINE; HUMAN; LYMPHADENECTOMY; MALE; PATHOLOGY; PATIENT SELECTION; PROSTATE TUMOR; PROSTATECTOMY; SHORT SURVEY; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 83455229330     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.09.006     Document Type: Short Survey

References (49)

1. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969.
2. Graefen M., Karakiewicz P.I., Cagiannos I., Quinn D.I., Henshall S.M., Grygiel J.J., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002, 20:3206.
3. Ross P.L., Gerigk C., Gonen M., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002, 20:82-88.
4. Kane C.J., Presti J.C., Amling C.L., Aronson W.J., Terris M.K., Freedland S.J. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007, 177:113-117.
5. Guérin S., Doyon F., Hill C. The frequency of cancer in France in 2006, mortality, trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends. Bull Cancer 2009, 96:51-57.
6. Coakley F.V., Qayyum A., Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003, 170:69-75.
7. Choi Y.J., Kim J.K., Kim N., Kim K.W., Choi E.K., Cho K.S. Functional MR imaging of prostate cancer. Radiographics 2007, 27:63-75.
8. Reinsberg S.A., Payne G.S., Riches S.F., Ashley S., Brewster J.M., Morgan V.A., et al. Combine use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. Am J Roentgenol 2007, 188:91-98.
9. Cornud F., Villers A., Mongiat-Artus P., Rebillard X., Soulie M. Magnetic resonance imaging and prostate cancer. Prog Urol 2008, 18(10):621-633.
10. Wolf J.S., Cher M., Dall'era M., Presti J.C., Hricak H., Carroll P.R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995, 153:993-999.
11. Katz S., Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006, 44:723-734.
12. Heesakkers R.A., Hö vels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
13. Weckermann D., Dorn R., Holl G., Wagner T., Harzmann R. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007, 51:1549-1558.
14. Lin K., Szabo Z., Chin B.B., Civelek A.C. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999, 24:579-582.
15. Lecouvet F.E., Geukens D., Stainier A., Jamar F., Jamart J., d'Othee B.J., et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost effectiveness and comparison with current detection strategies. J Clin Oncol 2007, 25(22):3281-3287.
16. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188(6):1622-1635.
17. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman radiation oncology group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:841-850.
18. Pilepich M., Winter K., Lawton C., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
19. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase IIII randomised trial. Lancet 2003, 360:103-108.
20. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
21. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
22. Warde P., Mason M., Sydes M., et al. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). J Clin Oncol 2010, 28(7s). [Abstr. CRA4504].
23. Mottet N., Peneau M., Mazeron J., et al. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. J Clin Oncol 2010, 28(15s). [abstr CRA 4505].
24. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
25. Bolla M, van Tienhoven G, de Reijke T, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation for locally advanced prostate cancer: 6 months versus 3 years ADT, results of the randomized EORTC phase III trial 22961. 2007 ASCO annual meeting proceedings part I. J Clin Oncol 2007;25:abs. 5014.
26. Tyrrell C.J., Payne H., See W.A., et al. Bicalutamide (Casodex) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer programme. Radiother Oncol 2005, 76:4-10.
27. Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.
28. Briganti A., Chun F.K., Salonia A., et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006, 50(5):1006-1013.
29. Weckermann D., Dorn R., Trefz M., Wagner T., Wawroschek F., Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007, 177:916-920.
30. Gofrit O.N., Zorn K.C., Steinberg G.D., Zagaja G.P., Shalhav A.L. The Will Rogers phenomenon in urological oncology. J Urol 2008, 179:28-33.
31. Salomon L., Azria D., Bastide C., Beuzeboc P., Cormier L., Cornud F., et al. Oncology Committee of the French Association of Urology (CCAFU). Recommendations Onco-Urology 2010: Prostate cancer. Prog Urol 2010, 20(suppl. 4):S217-S251.
32. Soulié M., Thoulouzan M., Péneau M., et al. Surgery of locally advanced prostate cancer. Prog Urol 2008, 18(13):1031-1037.
33. Van Den Ouden D., Hop W., Schröder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160:1392-1397.
34. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95:751-756.
35. Carver B.S., Bianco F.J., Scardino P.T., Eastham J.A. Longterm outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006, 176:564-568.
36. Johnstone P.A., Ward K.C., Goodman M., Assikis V., Petros J.A. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006, 106:2603-2609.
37. Boorjian S.A., Karnes R.J., Viterbo R., Rangel L.J., Bergstralh E.J., Horwitz E.M., et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011, 117(13):2883-2891.
38. Bolla M., Van Poppel H., Collette L., Van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC 22911). Lancet 2005, 366:572-578.
39. Thompson I.M., Tangen C.M., Paradelo J., Scott Lucia M., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomised clinical trial. J Urol 2009, 181:956-962.
40. Wiegel T., Lohm G., Bottke D., Hocht S., Miller K., Siegmann A., et al. Achieving an undetectable PSA after radiotherapy for biochemical recurrence after radical prostatectomy is an independent predictor of biochemical outcome - results of a retrospective study. Int J Rad Oncol Biol Phys 2009, 73:1009-1016.
41. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002, 90:561-566.
42. Klotz L.H., Goldenberg S.L., Jewett M.A., et al. Long-term follow up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003, 170:791-794.
43. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-479.
44. Wong Y.N., Freedland S., Egleston B., Hudes G., Schwartz J.S., Armstrong C. Role of androgen deprivation therapy in node-positive prostate cancer. J Clin Oncol 2009, 27:100-105.
45. McLeod D.G., See W.A., Klimberg I., Gleason D., Chodak G., Montie J., et al. The bicalutamide 150mg early prostate cancer program: findings of the North American trial at 7.7-year median follow-up. J Urol 2006, 176:75-80.
46. Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomised trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph-node negative prostate cancer. Eur Urol 2004, 45:267-270.
47. Moul J.W., Wu H., Sun L., Mc Leo D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
48. Tanya B.D., Thomas W.F., Catherine M.T., et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011, 29:2040-2045.
49. Garzotto M., Higano C.S., O'Brien C., Rademacher B.L., Janeba N., Fazli N., et al. Phase 1-2 study of preoperative docetaxel and mitoxantrone for high risk prostate cancer. Cancer 2010, 116:1699-1708.